Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
ALXN closed up 0.15 percent on Wednesday, April 26, 2017, on 85 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Apr 27
Trend Table & Recent Alerts
|Weak or Absent||Down||Down||Up|
|See historical ALXN trend table...|
|Date||Alert Name||Type||% Chg|
|Apr 26||Shooting Star Candlestick||Bearish||0.00%|
|Apr 26||Doji - Bearish?||Reversal||0.00%|
|Apr 26||Lizard Bearish||Bearish Day Trade Setup||0.00%|
|Apr 26||Stochastic Reached Overbought||Other||0.00%|
|Apr 26||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||0.00%|
|Apr 24||Bollinger Band Squeeze||Range Contraction||1.00%|
|Apr 21||Bollinger Band Squeeze||Range Contraction||3.35%|
|Apr 21||Cup with Handle||Other||3.35%|
|Apr 20||Bearish Engulfing||Bearish||1.69%|
|Apr 20||Bollinger Band Squeeze||Range Contraction||1.69%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Is ALXN a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ALXN news...
|52 Week High||157.02|
|52 Week Low||109.12|
|200-Day Moving Average||126.0792|
|50-Day Moving Average||123.4332|
|20-Day Moving Average||118.5035|
|10-Day Moving Average||118.682|
|Average True Range||2.9686|
|Chandelier Exit (Long, 3 ATRs)||114.0242|
|Chandelier Exit (Short, 3 ATRs)||122.3258|
|Upper Bollinger Band||122.6275|
|Lower Bollinger Band||114.3795|
|Percent B (%b)||0.77|